Sarepta Therapeutics, Inc.
SRPT
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Sarepta Therapeutics is a biopharmaceutical company focused on precision genetic medicines for rare diseases. The company's research and development pipeline, including its approved treatments for Duchenne muscular dystrophy (DMD), relies on preclinical animal testing as a standard regulatory requirement for drug development. This places its core business activity within the scope of commercial animal exploitation for research purposes.
While specific, recent documentation of Sarepta's animal testing protocols was not located in the provided evidence, the company's sector and product focus make such testing an inherent and material part of its operations. The development of genetic therapies typically involves extensive in vivo studies to demonstrate efficacy and safety prior to human trials. As a result, Sarepta's business model is contingent on the use of animals in research.
Sarepta Therapeutics develops and commercializes precision genetic medicines for rare diseases, a process that requires animal testing for regulatory compliance and product development. The company’s pipeline and approved therapies, including its AAVrh74 platform technology for gene therapies like Elevidys, rely on preclinical data from animal models to demonstrate safety and efficacy before human trials.
A 2024 Freedom of Information Act (FOIA) request specifically cited Sarepta Therapeutics, Inc. in relation to animal cruelty in FDA-funded research. While the full details of the request are not public, the citation links the company’s research activities to formal allegations of animal welfare concerns within the regulatory testing process. As a biotechnology firm focused on novel genetic therapies, Sarepta’s research and development model is inherently dependent on animal testing to advance its products through the regulatory pathway.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.